中慧生物-B(02627)：三价流感病毒亚单位疫苗的上市申请获国家药监局批准

Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for a new drug application for its trivalent influenza virus subunit vaccine, making it the first and only approved vaccine for all age groups in China [1] Group 1 - The vaccine is a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and a lower risk of adverse reactions [1]